By Steve Usdin
Contributing Editor

WASHINGTON - Biotech executives pressed the industry's case at the White House last week, telling a member of the president's staff that if the risk-reward ratio to investors is substantially altered, it could shatter the alliance between scientific talent and financial resources that has made the U.S. biotech industry pre-eminent in the world.